lightning strikes cells

What is FLASH radiotherapy?

Find out in our December issue

  • Marie-Catherine Vozenin
  • Jean Bourhis
  • Marco Durante


  • immune cells in lymph node and tumour

    "Clinical implications of T cell exhaustion for cancer immunotherapy" from A. Chow et al. will be freely available during the month after the publication of our December 2022 issue

  • viral particles

    Read all the COVID-19-related contents published in our journal, which will be freely available during the pandemic


    • Despite a considerable increase in research output over the past decades, the translation of radiomic research into clinically useful tests has been limited. In this Review, the authors provide 16 key criteria to guide the clinical translation of radiomics with the hope of accelerating the use of this technology to improve patient outcomes.

      • Erich P. Huang
      • James P. B. O’Connor
      • Lalitha K. Shankar
      Review Article
    • PADA-1 is the first trial to demonstrate benefit from a treatment-switching strategy guided by active monitoring of ESR1 mutations in plasma circulating tumour DNA (ctDNA) from patients with breast cancer. The results of this trial raise important questions about the specific treatment approach tested, and the feasibility of trials incorporating longitudinal ctDNA analyses to anticipate resistance and guide treatment.

      • Ben O’Leary
      News & Views
    • The first phase III trial to test perioperative immune-checkpoint inhibitor therapy for high-risk renal cell carcinoma yielded highly promising results, leading to regulatory approvals of adjuvant pembrolizumab. However, subsequent phase III trials, including the IMmotion010 trial of adjuvant atezolizumab, did not demonstrate similar benefits. Although molecular biomarkers are urgently needed to better delineate responder subgroups, the unique design of each trial might partially explain some of the patterns identified.

      • Chris Labaki
      • Toni K. Choueiri
      News & Views
    • Chimeric antigen receptor (CAR) T cells are effective therapies for patients with relapsed and/or refractory B cell malignancies, partly owing to the ability to target B cell-specific antigens. However, CAR T cells targeting solid tumour antigens are likely to carry a higher risk of on-target, off-tumour toxicity (OTOT). Here, the authors summarize the available data on OTOT in the context of CAR T cells targeting solid tumour antigens and describe novel CAR T cell designs that might overcome such toxicities.

      • Christian L. Flugel
      • Robbie G. Majzner
      • Mohamed Abou-el-Enein
      Review Article
    • CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved.

      • Richard T. Maziarz
      • Jordan Gauthier
      News & Views

Nature Careers